

<div><div><div><div></div><div>UnitedHealthcare</div><div>Community Plan</div></div></div><div>UnitedHealthcare Community Plan Pharmacy &amp; Therapeutics Committee Minutes</div></div>				
Meeting Date: June 5, 2025 Location: Via conference call/Teams				
Agenda Item	Speaker	Recommendation	Conclusions/ Recommendations	Vote
Meeting called to order		5:02PM EST		
A. Minutes from previous meetings		Review of Minutes from March 6, 2025	Minutes reviewed, approved	Yes
B. Hot Topic		Streamlining Pharmacy Prior Authorization Programs & Process - UHC Medicaid	Non-Voting Item	
		Dr. [REDACTED] said, I think it's great that you have taken this step. [REDACTED] replied, we definitely hear from our providers and know that the prior authorization process is challenging, so this is definitely something that is top of mind for us.		
C. Formulary Review - New Drugs		Aytrtek		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		<b>Tobramycin 5mL Inhaled Solution (Generic TOBI)</b>		
		Recommendation: • Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		<b>Tobramycin 4mL Inhaled Solution (Generic Bethkis)</b>		
		Recommendation: • Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Enrosol		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Aihemo		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Alttruby		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Crecessify		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Ensacove		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Journavx		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		<b>Naproxen EC Oral Tablet</b>		
		Recommendation: • Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Gomekii		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Tryngolza		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
D. Formulary Review - PDL Modifications		Confirm Review of PDL Modifications Grid	Yes/No	Yes
		Recommendation: • Asmanex HFA pMDI: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Asmanex Twisthaler DPI: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Accu-Chek (Guide, Aviva, Smartview) Test Strip: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Contour (Plus, Next) Test Strip: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • OneTouch (Verio, Ultra) Test Strip: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Ms. [REDACTED] commented, all members with these One Touch products are going to have to be supplied with new meters to accommodate the new strips that are preferred. [REDACTED] replied, great comment, thank you for bringing that up. It's actually something that we are working on with the manufacturers. They will be supplying meters to the members for free. If a member goes into the pharmacy and now has to switch to the Accu-Chek or Contour, the pharmacy will be supplied with an RX Bin and RX PCN, which allow the pharmacy to bill directly back to the manufacturer and the pharmacy will be able to provide the member with a free meter right there at the pharmacy. The manufacturer also has programs where they can send meters to providers offices and during an office visit, the members can receive the meter there as well. Additionally, the manufacturers have programs through their websites, where members can sign up directly through the manufacturers websites to receive meters.		



		Recommendation: • <b>Modafinil Oral Tablet:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Armodafinil Oral Tablet:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Ramelteon Oral Tablet:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Imatinib Oral Tablet:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Temozolomide Oral Capsule:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Abiraterone 250mg Oral Tablet:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Memantine ER Oral Capsule:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Donepezil 23mg Oral Tablet:</b> Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Februxostat Oral Tablet:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Prasugrel Oral Tablet:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Impavido Oral Capsule:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Freestyle Libre 3 CGM:</b> Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Freestyle Libre 3 Plus CGM:</b> Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Clemastine Oral Syrup:</b> Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Diphenhydramine Oral Elixir:</b> Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Fluoxetine Oral Tablet:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Paroxetine ER Oral Tablet:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Desvenlafaxine ER Oral Tablet:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Venlafaxine ER Oral Tablet:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Escitalopram Oral Solution:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Vilazodone Oral Tablet:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Sodium Polystyrene Sulfonate Powder for Solution:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Erxofin IM Injection:</b> Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Methadone 40mg tablet for oral solution:</b> Move to medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Methadone 10mg/ml, concentrated solution:</b> Move to medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		Recommendation: • <b>Hydrocortisone ampule (generic Solu-Cortef):</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
E. Formulary Review - New Drugs - Medical		Confirm Review of New Drugs- Medical Grid	Yes/No	Yes			
		<b>Zafiera</b>					
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		<b>Bizenri</b>					
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		<b>Ryoncil</b>					
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		<b>Datroway</b>					
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		<b>Kebildi</b>					
		Recommendation: • Medical benefit required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0			
		<b>Grafapex</b>					
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0			
		<b>Untoxcylt</b>					
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0			
F. Formulary Review - Drugs Evaluated Per		Apply recommendations as outlined in grid	Motion made,	11:0			
G. Clinical Guidelines		Clinical Guideline Review					
		Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	11:0			
		Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	11:0			
		Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	11:0			
H. Quality Monitoring		Confirm Review of Quality Data	Yes/No	Yes			
		DIR Review					
		Drug Recalls – 1st Quarter 2025					
		Top 25 Drugs by Spend and Volume – 1st Quarter 2025					
		Top 10 Drugs Requested - Approvals and Denials – 1st Quarter 2025					
		Grievances and Appeals Data – 1st Quarter 2025					
		Inter-Rater Reliability (IRR) – 1st Quarter 2025					
		• Pharmacists					
Adjournment		6:35PM EST					
Suggestions & Other Comments:	Comment	Please note that one of our committee members was not able to attend the meeting in its entirety. This in turn is reflected in the total number of voters for a few agenda items.					
Respectfully Submitted to the Committee,							
M.S.I.A., R.Ph. Chief Pharmacy Officer, UHC C&S							